Combination of PARP and KRAS G12D Inhibitors Enhances Efficacy of Therapeutic Vulnerabilities
RNA-seq (gene expression) · human · 30 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 30 samples: 10 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE279749_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1174198 and SRA study SRP539200. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 30 samples.
How we read this: 10 replicated groups read from 30 sample titles; they account for 30 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8579591 AsPC-1, vehicle_1 AsPC-1, vehicle
- GSM8579592 AsPC-1, vehicle_2 AsPC-1, vehicle
- GSM8579593 AsPC-1, vehicle_3 AsPC-1, vehicle
- GSM8579594 AsPC-1, MRTX1133_1 AsPC-1, MRTX1133
- GSM8579595 AsPC-1, MRTX1133_2 AsPC-1, MRTX1133
- GSM8579596 AsPC-1, MRTX1133_3 AsPC-1, MRTX1133
- GSM8579597 PANC-1, vehicle_1 PANC-1, vehicle
- GSM8579598 PANC-1, vehicle_2 PANC-1, vehicle
- GSM8579599 PANC-1, vehicle_3 PANC-1, vehicle
- GSM8579600 PANC-1, MRTX1133_1 PANC-1, MRTX1133
- GSM8579601 PANC-1, MRTX1133_2 PANC-1, MRTX1133
- GSM8579602 PANC-1, MRTX1133_3 PANC-1, MRTX1133
- GSM8579603 SW1990, vehicle_1 SW1990, vehicle
- GSM8579604 SW1990, vehicle_2 SW1990, vehicle
- GSM8579605 SW1990, vehicle_3 SW1990, vehicle
- GSM8579606 SW1990, MRTX1133_1 SW1990, MRTX1133
- GSM8579607 SW1990, MRTX1133_2 SW1990, MRTX1133
- GSM8579608 SW1990, MRTX1133_3 SW1990, MRTX1133
- GSM8579609 CFPAC-1, vehicle_1 CFPAC-1, vehicle
- GSM8579610 CFPAC-1, vehicle_2 CFPAC-1, vehicle
- GSM8579611 CFPAC-1, vehicle_3 CFPAC-1, vehicle
- GSM8579612 CFPAC-1, BI-2865_1 CFPAC-1, BI-2865
- GSM8579613 CFPAC-1, BI-2865_2 CFPAC-1, BI-2865
- GSM8579614 CFPAC-1, BI-2865_3 CFPAC-1, BI-2865
- GSM8579615 PDX, vehicle_1 PDX, vehicle
- GSM8579616 PDX, vehicle_2 PDX, vehicle
- GSM8579617 PDX, vehicle_3 PDX, vehicle
- GSM8579618 PDX, MRTX1133_1 PDX, MRTX1133
- GSM8579619 PDX, MRTX1133_2 PDX, MRTX1133
- GSM8579620 PDX, MRTX1133_3 PDX, MRTX1133
- GSE285857 Mutant KRAS-Driven Selective mRNA Translation Reveals Mechanisms and Therapeutic Vulnerabilities in Cancer 48 samples shares kras, vulnerabilities, therapeutic
- GSE306286 FOXO1 links KRAS G12D and G12V alleles to glutamine and nitrogen metabolism in colorectal cancer 16 samples shares kras, g12d
- GSE309499 HDAC5 Deficiency Induces Intrinsic Resistance to KRASG12D Inhibition by Disrupting c-Myc Acetylation-Ubiquitination Homeostasis [RNA-seq] 12 samples shares kras, g12d
- GSE290526 VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation [scRNA-Seq] 3 samples shares kras, g12d
- GSE225061 Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response 217 samples shares kras, combination
- GSE281517 Lysosomal sequestration of PARP inhibitors drives heterogeneous accumulation in ovarian cancer to increase efficacy [RNA-seq] 72 samples shares parp, inhibitors
- GSE315878 Lack of synergy between AR targeted therapies and PARP inhibition in homologous recombination- proficient prostate cancer 70 samples shares parp, combination
- GSE222556 Neoadjuvant PARPi or Chemotherapy in Ovarian Cancer Informs Targeting Effector Treg Cells for Homologous-Recombination-Deficient Tumors [10x scRNA-seq] 67 samples shares parp, combination
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.